Blood Cancer Patients Who Relapsed After Stem-Cell Transplant May Benefit from Immunotherapy
News
Patients with advanced hematologic cancers who relapse following allogenic hematopoietic stem cell transplantation (HSCT) have a very poor prognosis. Now, researchers at the Dana-Farber Cancer Institute have shown that the outcome ... Read more